

The PTO did not receive the following listed item(s) Any references that attached on PTO/SB/08

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

No fee is believed due with this submission. If, however, a fee is due, the Commissioner is authorized to charge it up to \$300.00 to Deposit Account No. 04-0100.

Dated: April 14, 2005

Respectfully submitted,

By 

Jay P. Lessler

Registration No.: 41,151

DARBY & DARBY P.C.

P.O. Box 5257


New York, New York 10150-5257

(212) 527-7700

(212) 527-7701 (Fax)

Attorneys/Agents For Applicant

04-18-05 JCO3 Rec'd PCT/PTO 14 APR 2009 PCT



Application No. (if known): 10/516,519 Attorney Docket No.: 05432/100L600-US1

Certificate of Express Mailing Under 37 CFR 1.10

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail, Airbill No. in an envelope addressed to:

EO 447562375-us

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

on April 14, 2005
Date


B.W. Lee
Signature

B.W. LEE
Typed or printed name of person signing Certificate

Registration Number, if applicable Telephone Number

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

IDS (Citation) by Applicant (2 pp); with
25 References attached
Information Disclosure Statement (2 pp)
Postcard



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete if Known		
			Application Number	10/516,519/Conf. #: 4458	
			Filing Date	November 29, 2004	
			First Named Inventor	Arne Mork	
			Art Unit	Not Yet Assigned	
			Examiner Name	Not Yet Assigned	
Sheet	1	of	2	Attorney Docket Number	05432/100L600-US1


U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴ -Kind Code ⁵ (if known)				
	BA	EP-0687472		20/12/95	Wong et al.		
	BB	EP-0701819		20/03/96	Chenard et al.		
	BC	EP-0714633		05/06/96	Ogulza et al.		
	BD	WO-9603400		08/02/96	Macor et al.		
	BE	WO-9728141		07/08/97	Halazy et al.		
	BF	WO-9913877		25/03/99	Berg et al.		
	BG	WO-9937303		29/07/99	Dawson et al.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	Kamatchi et al., <i>Brain, Research</i> , 586:181-186 (1990) "GABA _B receptor activation inhibits Ca ²⁺ -activated ⁸⁶ Rb-efflux in cultured spinal cord neurons via G-protein mechanism".	
	CB	Londborg et al., <i>Journal of Affective Disorders</i> (2000) 61:73-79, "Short-term cotherapy with clonazepam and fluoxetine: anxiety, sleep disturbance and core symptoms of depression".	
	CC	Blier et al., <i>TIPS</i> , 15:220-226 (July 1994); "Current advances and trends in the treatment of depression"	
	CD	Paredes et al. <i>Neuroscience and Biobehavioral Reviews</i> , Vol. 16 pp. 145-170 (1992), "GABA and Behavior: The Role of Receptor Subtypes"	
	CE	Hjorth, J. of <i>Neurochemistry</i> (1993) pp. 776-779, "Serotonin 5-HT _{1A} Autoreceptor Blockade Potentiates the Ability of the 5f-HT Reuptake Inhibitor Citalopram to Increase Nerve Terminal Output of 5-HT In Vivo: A Microdialysis Study"	

Examiner's Signature		Date Considered	
-------------------------	--	--------------------	--



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/516,519/Conf. #: 4458
				Filing Date	November 29, 2004
				First Named Inventor	Arne Mork
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	2	of	2	Attorney Docket Number	05432/100L600-US1

CF	Tao et al., <i>J. Psychopharmacology</i> 14(2)(2000) pp. 100-113, "Regulation of serotonin release by GABA and excitatory amino acids"
CG	F. Artigas, <i>TIPS - July 1993</i> (Vol. 14); "Letters - 5-HT and antidepressants: new views from microdialysis studies".
CH	Haefely, <i>Experimental Approaches to Anxiety and Depression</i> ; (1992); pp. 151-168, "The Role of GABA in Anxiolytic/Antidepressant Drug Action"
CI	Frydenvang, et al., <i>Chirality</i> 6:583-589 (1994) "GABA _B Antagonists: Resolution, Absolute Stereochemistry, and Pharmacology of (R)- and (S)Phaclofen"
CJ	Bowery, et al., <i>Pharmacol. Reviews</i> ; 54:247-264 (2002) Vol. 54, No. 2, "International Union of Pharmacology. XXXIII. Mammalian γ -Aminobutyric Acid _B Receptors: Structure and Function"
CK	Karla, <i>J. Med. Chem.</i> (1999) 42, pp. 2053-2059, "Synthesis and Pharmacology of Baclofen Homologues 5-Amino-4-(4-chlorophenyl)pentanoic Acid and the R- and S-Enantiomers of 5-Amino-3-(4-chlorophenyl)pentanoic Acid"
CL	Brauner-Osborne et al., <i>British J. Pharmacology</i> (1999) 128, 1370-1374, "Function pharmacology of cloned heterodimeric GABA _B receptors expressed in mammalian cells"
CM	Innis et al., <i>Europ. J. of Pharmacology</i> , 143 (1987) pp. 195-204, "Pertussis toxin blocks 5-HT _{1A} and GABA _B receptor-mediated inhibition of serotonergic neurons"
CN	Ivernizzi et al., <i>Brain Research</i> , 584 (1992) 322-324, "Citalopram's ability to increase the extracellular concentrations of serotonin in the dorsal raphe prevents the drug's effect in the frontal cortex"
CO	Tao et al., <i>British J. Pharmacology</i> (1996) 119, 1375-1384, "Differential regulation of 5-hydroxytryptamine release by GABA _A and GABA _B receptors in midbrain raphe nuclei and forbrain of rats"
CP	Gartside et al., <i>British J. Pharmacology</i> (1995) 1064-1070, "Interaction between a selective 5-HT _{1A} receptor antagonist and an SSRI in vivo: effects on 5-HT cell firing and extracellular 5-HT"
CQ	Blier et al., <i>J. Clinical Psychopharmacology</i> (1987) Vol. 7, pp. 24S - 35S, "Modifications of the Serotonin System by Antidepressant Treatments: Implications for the Therapeutic Response in Major Depression"

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner's Signature		Date Considered	
-------------------------	--	--------------------	--